Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Logothetis

Showing results (731-740 of 1,104) with videos related to

Pageof 111
Sort By:
Inorganic Chemistry|October 16, 2015
Gd(3+)-Based Magnetic Resonance Imaging Contrast Agent Responsive to Zn(2+)Martín Regueiro-Figueroa, Serhat Gündüz, Véronique Patinec, et al.
Cancers|January 23, 2020
Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate CancerFilippos Koinis, Paul Corn, Nila Parikh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomySara S Strom, Xuemei Wang, Curtis A Pettaway, et al.
Oncogene|December 3, 2003
A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cellsKevin B Spurgers, Kevin R Coombes, Raymond E Meyn, et al.
The Journal of Urology|February 26, 1999
p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potentialN M Navone, M E Labate, P Troncoso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancerPaul Mathew, Peter F Thall, Donnah Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancerEleni Efstathiou, Patricia Troncoso, Sijin Wen, et al.
Proteins|October 5, 2016
Three pairs of weak interactions precisely regulate the G-loop gate of Kir2.1 channelJunwei Li, Shaoying Xiao, Xiaoxiao Xie, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 15, 2020
Dynamic coupling of whole-brain neuronal and neurotransmitter systemsMorten L Kringelbach, Josephine Cruzat, Joana Cabral, et al.
The Prostate|March 30, 2012
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118bMaria Karlou, Jing-Fang Lu, Guanglin Wu, et al.
Pageof 111

Showing results (731-740 of 1,104) with videos related to

Sort By:
Pageof 111
Inorganic Chemistry|October 16, 2015
Gd(3+)-Based Magnetic Resonance Imaging Contrast Agent Responsive to Zn(2+)Martín Regueiro-Figueroa, Serhat Gündüz, Véronique Patinec, et al.
Cancers|January 23, 2020
Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate CancerFilippos Koinis, Paul Corn, Nila Parikh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomySara S Strom, Xuemei Wang, Curtis A Pettaway, et al.
Oncogene|December 3, 2003
A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cellsKevin B Spurgers, Kevin R Coombes, Raymond E Meyn, et al.
The Journal of Urology|February 26, 1999
p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potentialN M Navone, M E Labate, P Troncoso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancerPaul Mathew, Peter F Thall, Donnah Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancerEleni Efstathiou, Patricia Troncoso, Sijin Wen, et al.
Proteins|October 5, 2016
Three pairs of weak interactions precisely regulate the G-loop gate of Kir2.1 channelJunwei Li, Shaoying Xiao, Xiaoxiao Xie, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 15, 2020
Dynamic coupling of whole-brain neuronal and neurotransmitter systemsMorten L Kringelbach, Josephine Cruzat, Joana Cabral, et al.
The Prostate|March 30, 2012
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118bMaria Karlou, Jing-Fang Lu, Guanglin Wu, et al.
Pageof 111